REBIO TECHNOLOGIES

Sustained Treatment for Chronic Eye Diseases

ReBio is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. ReBio has leveraged Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases.

ReBIo_Eye_Drop.jpg

1. The Problem

25% of adults develop chronic eye disease, growing at 10% annually. Drops are unreliable for both patient and clinician, more often than not missing the target.

ReBio_Sisu.jpg

2. The Growing Answer

20M intravitreal injections per year globally for anti-VEGF treatments alone, some requiring monthly injections.

ReBio_Diagram_4.jpg

3. The Challenge:

Existing Sustained-Release methods have failed to deliver safe, effective, long-acting treatments.

ReBio_Sisu.jpg

4. The SiSu® Solution:

Depending on the indication, a single injection, or two injections per year to safely deliver sight-preserving treatment.